Karo Pharma Acquires Trimb Healthcare from Avista Capital Partners

Avista Healthcare Partners Acquires Trillium Health Care Products

August 7, 2024

Pharmaceuticals

Avista Healthcare Partners has completed the acquisition of Trillium Health Care Products, a Brockville, Ontario-based CDMO specializing in branded over‑the‑counter (OTC) products, from New Water Capital. Avista plans to invest in Trillium’s growth, expand its footprint and capabilities, and use the business as a consumer‑healthcare platform for potential strategic add‑on acquisitions.

KKR and Impilo Acquire Immedica Pharma

January 24, 2025

Pharmaceuticals

KKR and Nordic healthcare investor Impilo have completed a joint acquisition of Stockholm-based Immedica Pharma, with Immedica management reinvesting alongside the new owners. Immedica is a commercial-stage pharmaceutical company focused on rare and specialty diseases (notably hematology, oncology and genetic/metabolic disorders) with ~€100m revenue and more than 120 employees; CVC Credit provided debt financing and Impilo used a single-asset continuation fund supported by secondary investors.

Karo Pharma Acquires Sylphar International NV

January 13, 2023

Pharmaceuticals

Karo Pharma Aktiebolag has completed the acquisition of Belgian digital-first consumer health brand company Sylphar International NV for EUR 290 million. The deal is intended to strengthen Karo's market position and digital commerce capabilities; Sylphar CEO Robin List will join Karo's corporate management team and continue to lead Sylphar operations.

Avista Capital Partners Acquires WellSpring Consumer Healthcare

August 23, 2022

Consumer Products

Avista Capital Partners completed the acquisition of WellSpring Consumer Healthcare from Audax Private Equity. WellSpring, founded in 1999 and headquartered in Sarasota, Florida, is a developer and marketer of over-the-counter and personal care brands (including Bactine, Bonine, Emetrol and Glaxal Base); Avista plans to support growth through product innovation, distribution expansion and strategic acquisitions.

Blackhawk Growth Corp Acquires Trip Pharma Inc.

October 13, 2020

Healthcare Services

Blackhawk Growth Corp. completed the acquisition of all outstanding shares of Trip Pharma Inc., an Edmonton-based psychedelic development and wellness company led by Dr. Krista Leicht. The transaction was satisfied largely with issuance of common shares to Trip Pharma shareholders and brings Trip Pharma into Blackhawk's existing healthcare/cannabis investment portfolio as it pursues clinical research and a psychiatric research clinic focused on psilocybin-based therapies.

Cambrex Acquires Avista Pharma Solutions

January 2, 2019

Pharmaceuticals

Cambrex Corporation completed the acquisition of Avista Pharma Solutions from Ampersand Capital Partners in a transaction announced November 20, 2018 and completed January 2019 (reported consideration about $252 million). The deal brings Avista’s early‑stage drug development, analytical/testing and finished dosage capabilities (sites in Longmont, CO; Durham, NC; Agawam, MA; and Edinburgh, UK) into Cambrex’s global CDMO network to expand capabilities and cross‑sell services.